BioSpace News Archive

- During this Unprecedented Time with the COVID-19 Pandemic, Patients Continue to Elect Participation in this Important Trial

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PTG-300 in the treatment of polycythemia vera, a rare disease characterized by the excessive production of red blood cells. PTG-300 is an injectable synthetic peptide mimetic of the nat

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and commercial overview on its pipeline programs in status epilepticus, CDKL5 deficiency disorder, and Tuberous sclerosis complex, on Monday, December 7 from 12:00 PM – 2:00 PM Eastern time.

CytoSorbents Corporation announces the launch of its international fundraising campaign to raise $100,000 to benefit the global, not-for-profit humanitarian organization, CARE USA.

Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced the appointment of Paolo Pucci as a new Board Director.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and liver disease,

The global automated radiosynthesis modules market is forecasted to be a million-dollar opportunity for industry participants expected to be encouraged by a colossal demand in the recent years.

FasterCures, a center of the Milken Institute devoted to accelerating biomedical innovation, launched an initiative to build a global “early warning system” that detects and responds to emerging pathogens with pandemic potential.

The rising adoption of pets and the increasing awareness among people regarding the animal health are projected to accelerate the growth of the market in the next few years.

All corporate information, such as the Company’s financial statements and corporate presentations, is available on https://investors.innate-pharma.com.